Technology News and Research

RSS

Clinton signs new $10 million agreement on HIV/AIDS with Angola, says U.S. 'stands ready' to work with South Africa on HIV/AIDS

Secretary of State Hillary Rodham Clinton signed a new agreement with Angola aimed at controlling the spread of HIV/AIDS, the Associated Press reports. "The Obama administration will more than double funding for Angola to combat the disease, from $7 million to $17 million," the news service writes (Lee, 8/10).

10 Aug 2009

Cephalon, Inc. completes acquisition of Arana Therapeutics

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

10 Aug 2009

CDC expands existing vaccine distribution partnership with Mckesson to include H1N1 flu vaccine

McKesson Corporation (NYSE:MCK) today announced that its current partnership with the Centers for Disease Control and Prevention (CDC) has been expanded to include preparations for H1N1 flu vaccine distribution. The CDC currently has a contract with McKesson for distribution of its public-sector purchased adult and pediatric vaccines, including those distributed through the Vaccines for Children Program.

10 Aug 2009

Automated dispensing unit provides more accurate pharmacy automation

For central fill and mail order pharmacies looking to move their unit-of-use dispensing and pre-pack dispensing from A-frames to more accurate pharmacy automation, Tension International Automation Solutions (TIAS) offers the ADU-3500L. The automated dispensing unit (ADU) automates the dispensing, labeling and verification of pre-packaged products, and pharmaceutical and nutraceutical units-of-use.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Mal-illumination - the silent epidemic

Most of human history has witnessed people living and working outdoors during the light of day, absorbing "life-charging" full-spectrum solar energy from the sky. An average of 10 hours daily in the sunlight, 70 hours weekly, was common for eons.

10 Aug 2009

Curemark closes $6.5 million Series A round of funding

Curemark, a privately held drug research and development company, announced today that it has closed a $6.5M Series A round of funding.

10 Aug 2009

ISI to host eSolutions Conference in September 2009

Image Solutions Inc. (ISI), a leading provider of electronic submissions management and publishing solutions for the life sciences industry, has unveiled a prestigious line-up of speakers for its annual eSolutions Conference in Barcelona, Spain, this September to support an agenda aimed at reinventing the regulatory function.

10 Aug 2009

Electronic health records cut cardiac deaths by 73 percent

An innovative program that cut cardiac deaths by 73 percent by linking coronary artery disease patients and teams of pharmacists, nurses, primary care doctors, and cardiologists with an electronic health record also kept the patients healthy two years after they left the program by keeping them in touch with their care givers electronically, according to a randomized study by Kaiser Permanente published in The American Journal of Managed Care this month.

9 Aug 2009

Chemists rationally design inhibitors against an RNA molecule that causes myotonic muscular dystrophy

Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.

9 Aug 2009

Merge Healthcare to acquire Confirma

In order to combine forces on expanding CAD technology, Merge Healthcare Incorporated, a leading health IT solutions provider, and Confirma, Inc., the largest privately-held developer of computer assisted detection (CAD) software for medical imaging, announce that they have entered into a definitive agreement for Merge to acquire Confirma in an all-stock transaction. This acquisition brings Confirma’s patented and proven technologies to Merge’s multiple market channels and international markets, and provides a mechanism to expand adoption of this important technology.

9 Aug 2009

State Governments join push for health IT

State governments around the country are working to facilitate, and in some cases, enhance, Washington's stimulus-funded incentives for doctors and hospitals that adopt new health information technology.

7 Aug 2009

Scientists study affect of carbon nanoparticles on fruit flies

Carbon nanoparticles are widely used in medicine, electronics, optics, materials science and architecture, but their health and environmental impact is not fully understood.

7 Aug 2009

LDTD Technology at BASi increases speed of sample analysis

BASi provides clients with increased sample analysis speed and quick turnaround with the LDTD technology. Fast screening is combined with accurate quantification results, to benefit any bioanalytical studies.

7 Aug 2009

Pending health care reform should not distract from making medical technology investments

In spite of the tremendous attention being paid this summer to health care reform, it is critical that investments in medical technology startups not go into a “holding pattern,” but continue unabated. So says ONSET Ventures partner Rob Kuhling.

6 Aug 2009

GE Global Research Biosciences technology celebrated fifth anniversary

From creating a new business in digital pathology to developing next generation diagnostic imaging agents and life sciences tools that are breaking new ground in the detection and treatment of disease, the Biosciences technology organization at GE Global Research today celebrated its fifth anniversary.

6 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.

6 Aug 2009

Celera and Aurora to collaborate on cardiovascular genetics

Aurora Health Care, Wisconsin's largest health care provider, and Celera Corporation announced today that they have entered into an agreement to collaborate on the integration of genetic testing aimed at optimizing heart care for Aurora patients

6 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009